

# FREDUN PHARMACEUTICALS LIMITED

*Compassionate Healthcare*



CIN No : L24239MH1987PLC043662

Date: 28<sup>th</sup> November, 2022

To,

**BSE Ltd.,**

Listing Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street - Fort,  
Mumbai - 400 001

Ref.: BSE Scrip Code - 539730

**Subject: Disclosure under Regulation 30 of Securities and Exchange Board of India  
(Listing Obligations And Disclosure Requirements) Regulations, 2015**

Dear Sir / Madam,

In compliance to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; we hereunder furnish a press release regarding receipt of multiple contracts from Southeast Asian country for Pharma exports.

Kindly take the same on your Records.

Thanking you,

**For Fredun Pharmaceuticals Limited**

---

**Fredun Nariman Medhora**  
**Managing Director**  
**DIN: 01745348**

**Registered Office:** Manoj Industrial Premises, G.D. Ambekar Marg, Wadala (W), Mumbai - 400 031, (INDIA)

**Corporate Office:** Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.

**Phone No.:** 91-22- 4031 8111 **Fax:** 91-22-4031 8133

**Factory:** 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

**Phone No.:** +917045957828, +917045957829, +917045957830, +917045956857

**E-Mail:** [business@fredungroup.com](mailto:business@fredungroup.com) **Web:** [www.fredungroup.com](http://www.fredungroup.com)



# FREDUN PHARMACEUTICALS LIMITED

Press Release  
For Immediate Dissemination

## PRESS RELEASE

### Fredun Pharmaceuticals bags multiple contracts

Mumbai, India | November 28, 2022

Fredun Pharmaceuticals Limited (BSE: 539730), a leading healthcare and pharmaceuticals company, has signed two large contracts for Pharma and DC Granules.

The Company received one-year contract worth Rs. 65 crores from a Southeast Asian country for Pharma exports. The revenue would commence from Q4FY23. This is part of a much larger multiple-year contract and will be continued upon successful execution post first year.

The Company further signed a contract for specialized DC granules for various therapeutic end uses. The annual contract is worth Rs. 25 crores and has the potential to go up to Rs. 40 crores from second year onwards. These DC Granules will be exported as well as supplied to local companies across India. Revenues from this contract would commence from Q4FY23 as well.

***Commenting on the order wins, Mr. Fredun Medhora, Managing Director of Fredun Pharmaceuticals said, "We are delighted to grow our footprint in the Southeast Asian market that has tremendous opportunities. These contract wins are an important step in taking Fredun Pharmaceuticals to the next level. This reflects our capabilities that can be leveraged to further fuel growth for the Company."***



# FREDUN PHARMACEUTICALS LIMITED

## About Fredun Pharmaceuticals

Fredun Pharmaceuticals Limited, healthcare and pharmaceuticals company offer a range of products, including antihypertensives, antidiabetic, antiretroviral drugs (ARVs) and narcotics. It is also engaged in the manufacturing of dietary/herbal supplements, nutraceuticals, cosmeceuticals, and other healthcare products along with animal healthcare products. With such a diverse range of products, the Company's objective is to be a holistic healthcare provider. The Company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America.

For further details, please feel free to contact:

### Investor Relations team at Fredun Pharmaceuticals Limited

#### Fredun Medhora

Managing Director, Fredun Pharmaceuticals Ltd

P: 022-4031 8111

E: [investing@fredungroup.com](mailto:investing@fredungroup.com)

#### Runjhun Jain/Sonia Keswani

Ernst & Young LLP

M: 98207 20993 / 80173 93854

E: [runjhun.jain1@in.ey.com](mailto:runjhun.jain1@in.ey.com) / [sonia.keswani@in.ey.com](mailto:sonia.keswani@in.ey.com)

#### Registered Office

26, Manoj Industrial Premises,

G.D. Ambedkar Marg, Wadala,

Mumbai – 400 031

#### Corporate Office

'Urmi Estate', 11<sup>th</sup> Floor,

Ganpatrao Kadam Marg, Lower Parel

(W),

Mumbai – 400 013

Tel. No.: +91 22 4031 8111

## Disclaimer:

*This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Fredun and its subsidiaries/associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, change in laws and regulations that apply to pharmaceuticals, increasing competition in and changes in political conditions in India. Neither Fredun, nor our Directors, or any of our subsidiaries/associates assume any obligation to update any particular forward-looking statement contained in this release. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.*